ATC Group: G04CB Testosterone-5-alpha reductase inhibitors

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of G04CB in the ATC hierarchy

Level Code Title
1 G Genito urinary system and sex hormones
2 G04 Urologicals
3 G04C Drugs used in benign prostatic hypertrophy
4 G04CB Testosterone-5-alpha reductase inhibitors

Group G04CB contents

Code Title
G04CB01 Finasteride
G04CB02 Dutasteride
G04CB51

Active ingredients in G04CB

Active Ingredient Description
Dutasteride

Dutasteride reduces circulating levels of dihydrotestosterone (DHT) by inhibiting both type 1 and type 2, 5α-reductase isoenzymes which are responsible for the conversion of testosterone to DHT.

Finasteride

Finasteride is a competitive inhibitor of human 5α-reductase, an intracellular enzyme which metabolises testosterone into the more potent androgen, dihydrotestosterone (DHT). In benign prostatic hyperplasia (BPH), enlargement of the prostate gland is dependent upon the conversion of testosterone to DHT within the prostate. Finasteride is highly effective in reducing circulating and intraprostatic DHT. Finasteride has no affinity for the androgen receptor.

Related product monographs

Title Information Source Document Type  
Avodart 0.5mg soft capsules Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
FINCAR Tablet Web Search MPI, US: SPL/PLR
FINIDE Film-coated tablet Pharmaceutical Benefits Scheme (AU) MPI, EU: SmPC
PROSCAR Film-coated tablet Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC